POLD1 and cancer: Pan-cancer analyses reveal that patients with POLD1-mutated tumors achieve superior outcomes with ICIs, including prolonged overall survival (34 months for POLD1-mutated vs. 18 months for wild-type MSS tumors) and response rates > 80% in some studies (31, 63).